Blog Empty Image

Which of the following information about Naloxone Auto-Injector (Evzio) is/are TRUE?
 
I. It is indicated for treating a suspected opioid overdose.
 
II. The principal advantage of Naloxone is that it doesn't cause withdrawal symptoms such as sweating, increased heart rate or agitation even in an opioid dependent patient.
 
III. A person should use great caution to administer Naloxone to someone who is not using opioids.
 
a. I only
b. I and II only
c. All
d. None of the above


Which of the following information about Naloxone Auto-Injector (Evzio) is/are TRUE?
 
I. It is indicated for treating a suspected opioid overdose.
 
II. The principal advantage of Naloxone is that it doesn't cause withdrawal symptoms such as sweating, increased heart rate or agitation even in an opioid dependent patient.
 
III. A person should use great caution to administer Naloxone to someone who is not using opioids.
 
a. I only
b. I and II only
c. All
d. None of the above

Answer: (a) I is True only. Naloxone HCL (Evzio) is a pre-filled, single-use auto-injector. Naloxone HCL (Evzio) is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
 
Naloxone HCL (Evzio) is intended for immediate administration as emergency therapy in settings where opioids may be present. It is for intramuscular and subcutaneous use only. Administer the initial dose of Naloxone HCL (Evzio) to adult or pediatric patients intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. There's no harm in giving Naloxone HCL (Evzio) to someone who is not using opioids.
 
Naloxone HCL (Evzio) can trigger withdrawal symptoms such as sweating, increased heart rate, or agitation in the opioid dependent patient. Hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest are commonly reported side effects of Naloxone HCl (Evzio).